DEM301
Gastrointestinal Cancers / Solid Tumors
Pre-clinicalActive
Key Facts
About DEM BioPharma
DEM BioPharma is a private, pre-clinical stage biotech pioneering a novel approach to cancer immunotherapy by engaging macrophages. The company's core technology involves developing therapeutics designed to redirect and activate macrophages to attack solid tumors, an area with significant unmet need. While still early-stage, the planned presentation of preclinical data for its lead candidate, DEM301, at a major oncology conference in 2026 indicates progress. The company operates as a typical venture-backed biotech, seeking to advance its pipeline through preclinical and clinical development to create value for patients and investors.
View full company profile